PDS Biotech Completes PIPE Financing and Reports Q3 2026 Results
The company reported third quarter financial results and clinical updates, including the completion of a $22.3 million PIPE financing and the publication of Phase 2 trial results for PDS0101 in JAMA Oncology.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed